Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Tag: patient-centered care

ChiroMedBlogpatient-centered care

Cardiometabolic Health Solutions With GLP-1 Therapy

Discover the impact of GLP-1 therapy on cardiometabolic health and how it can benefit individuals seeking better wellness.

Abstract: A New Paradigm in Metabolic Health

Welcome to our educational post on the revolutionary class of medications known as GLP-1 receptor agonists. As a practitioner deeply rooted in integrative and functional medicine, with a diverse background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), my primary goal has always been to find the most effective, evidence-based strategies to improve my patients’ health. My clinical observations at our El Paso and San Antonio clinics, coupled with the latest research, continually point toward a more integrated and holistic approach to chronic disease. This post will serve as your guide, translating complex clinical trials and physiological mechanisms into an easy-to-understand narrative. We will delve into how these powerful agents work, explore the landmark cardiovascular outcomes trials (CVOTs) that revealed their ability to protect the heart and kidneys, and differentiate among the available options, such as semaglutide (Ozempic/Wegovy) and the dual-agonist tirzepatide (Mounjaro/Zepbound). Furthermore, we will delve into the practical aspects of using these therapies, including managing side effects, understanding safety considerations, and exploring their investigational uses in everything from neuroprotection to fertility. Most importantly, we’ll connect these pharmacological advancements back to the core principles of integrative health, examining how integrative chiropractic care is essential for maximizing patient outcomes and achieving true, sustainable well-being.

Rethinking Diabetes: Beyond Glucose-Centric Care

In my years of practice, I’ve seen firsthand the devastating impact of diabetes on my patients’ lives. For decades, the management of type 2 diabetes was primarily focused on lowering blood glucose levels. However, we now understand that this is only one piece of a much larger puzzle. It’s a reality underscored by stark statistics. We know that atherosclerotic cardiovascular disease (ASCVD)—which encompasses coronary heart disease, stroke, and peripheral arterial disease—is the leading cause of death for individuals with type 2 diabetes. In fact, more than 70% of elderly patients with diabetes will likely succumb to heart disease or a stroke. The prognosis following a heart attack is significantly poorer for someone with diabetes compared to someone without, and alarmingly, these outcomes often remain bleak even when blood glucose levels are considered “well-controlled.”
This has forced a critical shift in our clinical strategy. The old model, which I call the “glucose-centric” approach, is no longer sufficient. We must move toward a multifaceted management plan that reduces overall risk. This requires a collaborative and integrative effort.

Pillars of Modern Diabetes Management

The world’s leading medical bodies, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease Improving Global Outcomes (KDIGO) group, are all aligned on this new, comprehensive approach. It’s no longer just about the A1c. Our focus must be on:
Lifestyle Management: Foundational changes in diet and physical activity.
Diabetes Self-Management Education: Empowering patients with the knowledge to control their condition.
Cardiovascular Risk Reduction: Aggressively managing blood pressure, cholesterol (lipids), and, of course, glucose levels.
Weight Management: Addressing excess weight as a key driver of metabolic dysfunction.
Smoking Cessation: Eliminating a major accelerator of cardiovascular disease.
This holistic view is the cornerstone of effective, 21st-century care.

Clinical Case Study: The Challenge of “Over-Basalization”

To illustrate these concepts, let’s consider a case similar to many patients I see in my clinic. We’ll call her Naomi.
Naomi is a 66-year-old female who has been living with type 2 diabetes for 12 years. Despite being on a robust medication regimen, her health is not where it needs to be.
A1c: Her last A1c was 8.3%, well above the target of less than 7%.
Comorbidities: She has high cholesterol (hyperlipidemia), hypertension, and protein in her urine (proteinuria), a sign of early kidney stress.
Medications:
Metformin 1000 mg twice daily.
Degludec insulin (a basal insulin): 66 units daily.
An SGLT-2 inhibitor (a class of oral diabetes medication).
A statin for cholesterol.
An ARB for blood pressure.
Weight: She weighs 220 pounds and is 5’9 “, giving her a BMI of 32.5, placing her in the obese category.
Glucose Readings:
Her fasting glucose levels are between 140 and 160 mg/dL. The goal is typically 90-130 mg/dL.
Her postprandial (after-meal) glucose levels are 160-170 mg/dL. While the ADA goal is under 180 mg/dL, many specialists, including myself, prefer to see this number much lower, ideally under 140 mg/dL two hours after a meal.

The Problem: Over-Basalized and Still Not at Goal

Naomi’s case highlights a common clinical problem: “over-basalization.” She is taking a very high dose of basal insulin, yet her A1c and fasting glucose are still too high. A simple clinical calculation I use is to multiply a patient’s weight in kilograms by 0.5. For Naomi, who weighs 100 kg, this suggests that a basal insulin dose above 50 units may be excessive. At 66 units, she is clearly over-basalized.
The high basal insulin dose isn’t effectively controlling her blood sugar, and it’s likely contributing to her difficulty with weight management. The logical next step in a traditional model might be to add prandial (mealtime) insulin to cover her post-meal glucose spikes. However, this is where we can intervene more intelligently. Before adding more insulin, which often leads to further weight gain and increased risk of hypoglycemia, we should consider a GLP-1 receptor agonist. This approach leverages the body’s natural “incretin effect” to address the very issue Naomi is struggling with: postprandial hyperglycemia.

Understanding GLP-1 Receptor Agonists: The Incretin Effect

To truly appreciate these medications and understand why a GLP-1 agent is such a powerful tool, we need to talk about the “incretin effect.” This term describes a fascinating physiological process that is glucose-dependent, meaning these hormones act primarily when glucose is present. Our bodies naturally produce incretin hormones, specifically GLP-1 (Glucagon-Like Peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which are synthesized and released by specialized “L-cells” in the jejunum, a part of our small intestine.
This release is triggered by the presence of food in the gut. When you eat a meal, these hormones are secreted into the bloodstream, orchestrating a multi-pronged response:
Stimulates Insulin Secretion: It signals the pancreas to increase insulin secretion, but only in a glucose-dependent manner. This means it only works when blood sugar is high, dramatically reducing the risk of hypoglycemia compared to insulin or other medications.
Suppresses Glucagon Release: It signals the pancreas to stop releasing glucagon, a hormone that prompts the liver to produce more glucose. This prevents unnecessary glucose from entering the bloodstream.
Slows Gastric Emptying: It slows down the rate at which food leaves the stomach. This makes you feel full sooner and for longer, helping to control appetite and prevent sharp, rapid spikes in blood sugar after meals.
Promotes Satiety: It acts directly on the brain to reduce appetite and increase feelings of fullness.
In individuals with type 2 diabetes, this natural incretin effect is often blunted or, in some cases, completely absent. They produce very low levels of their native GLP-1 hormone. This deficiency leads to insufficient insulin secretion after meals and a failure to suppress glucagon. The result is the hallmark hyperglycemia we see in diabetes. GLP-1 receptor agonists are medications designed to mimic the action of our own GLP-1, but they are engineered to last much longer in the body, restoring and amplifying these beneficial effects.

Mechanisms of Action: More Than Just Blood Sugar Control

The mechanisms of these drugs are multifaceted and explain not only their benefits but also their common side effects.
Gastrointestinal System: In the presence of a GLP-1 agonist, gastric emptying is significantly slowed. This delay is a primary reason patients feel full for longer, which naturally leads to reduced food intake and contributes to weight loss. Unfortunately, this slowing effect can also cause side effects like mild nausea and occasionally vomiting, especially in individuals with a history of gastroparesis. Some patients may experience diarrhea, while others report constipation or mild abdominal pain.
Central Nervous System (Brain): We believe that these small-molecule drugs can cross the blood-brain barrier and act directly on the brain’s appetite centers, such as the hypothalamus. This central action helps to decrease appetite and reduce food cravings, providing another powerful mechanism for weight loss. The feeling of prolonged satiety is likely a combination of this central effect and the delayed gastric emptying.
Pancreas: In the pancreas, GLP-1 agonists stimulate glucose-dependent insulin secretion from the beta cells. Simultaneously, they suppress glucagon secretion. By lowering glucagon, they help reduce the liver’s inappropriate production and release of stored glucose, a common dysfunction in type 2 diabetes.

The “Ominous Octet” and the Power of GLP-1s

In 2009, the renowned endocrinologist Dr. Ralph DeFronzo published a seminal paper describing the “Ominous Octet”—eight core pathophysiological defects that contribute to type 2 diabetes (DeFronzo, 2009). This framework helps us understand the complexity of the disease. What is remarkable is that GLP-1 receptor agonists address six of these eight defects very effectively. Their widespread use makes them among the most comprehensive therapies available.

Choosing the Right GLP-1 Agonist: A Comparative Look

The family of GLP-1 agents has grown, offering us a variety of options with distinct profiles. It’s crucial to choose an agent that aligns with the individual patient’s needs. Let’s look at the data from leading researchers to understand the impact of these medications. When we compare these agents, we see a clear progression in efficacy:
Liraglutide resulted in a weight loss of about 2.7 kilograms and a just under 1% reduction in HbA1c.
Dulaglutide improved upon this, showing an average weight loss of 4.6 kilograms.
Semaglutide represented a significant leap forward, demonstrating an average weight loss of 6.4 kilograms and a more robust HbA1c reduction of between 1.8% and 2.1%.
Then came tirzepatide, a dual GIP and GLP-1 receptor agonist, which has shown truly remarkable results. In clinical trials, it was associated with an average weight loss of 11.2 kilograms—almost double that of semaglutide—and an impressive 2.3% reduction in HbA1c.
It’s crucial to note that these powerful results, particularly for weight loss, were observed at the higher doses approved by the FDA during the drug approval process. Here’s a breakdown of the key players, based on the latest research and FDA indications as of May 21, 2026:
Medication (Brand Name)
Key Indications & Benefits
A1c Lowering
Typical Weight Loss
Semaglutide (Ozempic/Rybelsus)
Type 2 Diabetes, Weight Loss (Wegovy), MACE Reduction, Nephropathy Protection. Semaglutide is a potent agent with robust evidence of cardiovascular and kidney benefits.
~1.5-2.0%
~15% of body weight
Tirzepatide (Mounjaro/Zepbound)
Type 2 Diabetes, Weight Loss, OSA. This is a “twincretin,” a dual GLP-1/GIP agonist, showing the highest efficacy for both glucose lowering and weight loss. Cardiovascular outcome trials are ongoing but look promising.
>2.0%
>20% of body weight
Dulaglutide (Trulicity)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. A reliable weekly injection with proven cardiovascular and kidney benefits, though with more moderate weight loss compared to newer agents.
~1.0-1.5%
~3-5 kg
Liraglutide (Victoza)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. One of the first GLP-1s with proven cardiovascular benefits, but it requires a daily injection. Weight loss is more modest. A higher dose is available for weight loss (Saxenda).
~1.1%
~2.5 kg
Exenatide (Byetta/Bydureon)
Type 2 Diabetes. One of the earliest GLP-1s. It is effective for glucose control but has less impact on weight and lacks the proven cardiovascular protection of newer agents.
<1.0%
~2.9 kg
MACE = Major Adverse Cardiovascular Events (heart attack, stroke, cardiovascular death). OSA = Obstructive Sleep Apnea.
 
 
 
When I select a GLP-1 agonist for a patient, I’m not just looking at the A1c. For Naomi, who has hypertension and proteinuria, choosing an agent with proven MACE reduction and nephropathy protection like semaglutide (Ozempic) or dulaglutide (Trulicity) would be a critical part of a comprehensive strategy. Given her significant need for weight loss and A1c reduction, semaglutide or tirzepatide would be the top consideration.

Cardiovascular Outcomes Trials (CVOTs): The Game-Changer

The history of diabetes medications is marked by a pivotal moment in 2008. Following safety concerns with earlier drugs, the FDA mandated that all new diabetes drugs undergo large, long-term Cardiovascular Outcomes Trials (CVOTs). The goal was to demonstrate that these new drugs did not harm the cardiovascular system.
What happened next was completely unexpected and revolutionized our field. Not only were these drugs safe, but they also provided robust cardiovascular risk reduction. This discovery shifted the paradigm from “just diabetes drugs” to essential tools for cardiologists and nephrologists. The GLP-1 receptor agonists soon followed with their own impressive CVOT data:
REWIND Trial (Dulaglutide): Showed a 12% reduction in major adverse cardiovascular events (MACE).
LEADER Trial (Liraglutide): Showed a 13% reduction in MACE.
SUSTAIN-6 Trial (Subcutaneous Semaglutide): Showed a remarkable 26% reduction in MACE.
These large, multi-year, double-blind, placebo-controlled studies involving thousands of patients solidified the role of these medications as cornerstones of cardio-renal-metabolic care. We now view metabolic disease through the lens of the cardio-renal-metabolic (CRM) triad. These systems are bidirectionally linked; a problem in one inevitably affects the others.

How Professional Guidelines Position GLP-1 Agonists

The American Diabetes Association (ADA) has recognized the profound benefits of these medications. The 2025 ADA guidelines, published annually in Diabetes Care, place a strong emphasis on GLP-1 receptor agonists, especially for certain patient populations (ElSayed et al., 2024).
The ADA treatment algorithm is divided into two main pathways:
The Left-Hand Pathway: For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), or those at very high risk. For these patients, a GLP-1 receptor agonist is now strongly favored as a primary agent, sometimes even before metformin.
The Right-Hand Pathway: For patients whose primary needs are glycemic control and weight management but who do not have the high-risk cardiovascular or kidney profile.
For patients with CKD, SGLT2 inhibitors are often the first choice. However, certain GLP-1 agonists, specifically semaglutide, have also earned an indication for kidney protection. The FLOW trial, stopped early due to overwhelmingly positive results, demonstrated that semaglutide reduced the risk of major kidney disease events and cardiovascular death by 24% in people with type 2 diabetes and CKD.

Balancing Body and Metabolism- Video

Navigating the Switch: A Guide to Changing GLP-1 Agonists

As a clinician committed to patient-centered care, I often encounter scenarios in which a medication switch is considered. A recent case involved a patient, we’ll call her Tammy, who was on Trulicity (dulaglutide) but wasn’t achieving her desired weight loss. Through shared decision-making, we explored a switch. This requires a careful, evidence-informed approach.
Switching from Trulicity (dulaglutide) to Ozempic (semaglutide): To switch from a 1.5 mg dose of dulaglutide, I would begin her on semaglutide 0.5 mg weekly. This conservative start minimizes side effects. After a month, if she tolerates it well, we could increase her to a weekly dose of 1 mg.
Switching from Trulicity (dulaglutide) to Mounjaro (tirzepatide): After her last dose of Trulicity, we would wait a full week (a “washout” period) before starting tirzepatide. I would initiate treatment with tirzepatide 5 mg weekly. The goal is to find the optimal dose—the one where the patient achieves significant satiety and weight loss with minimal side effects—by titrating up every four weeks if needed.

The Expanding Universe of GLP-1 Receptor Agonists

The story of GLP-1 agonists is no longer confined to diabetes. The research community is buzzing with discoveries about their far-reaching benefits.

Metabolically Associated Steatotic Liver Disease (MASLD)

One of the most promising frontiers is in liver health. The primary benefit for MASLD and its inflammatory progression, MASH, comes from the significant and sustained weight loss these drugs induce, which directly decreases fat deposition in the liver (Abbasi, 2024). Novo Nordisk is seeking FDA approval for this indication, which we may see by late 2025 or early 2026.

Expanding Indications: Beyond Diabetes

The benefits have proven to extend beyond patients with type 2 diabetes, as established by two landmark trials:
STEP-HFpEF Trial: This study showed that in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide led to significant improvements in heart failure symptoms and physical limitations, regardless of whether the patients had diabetes (Kosiborod et al., 2023).
SELECT Trial: This trial involved over 17,000 overweight or obese patients with pre-existing heart disease but without diabetes. The group receiving semaglutide showed a 20% reduction in MACE compared to placebo.

Cravings, Compulsive Behaviors, and Addiction

A consistent report from my own patients is a dramatic reduction in cravings. They describe it as a quieting of the constant “food noise” in their brain, with a decreased desire for alcohol and smoking. This points to a fundamental impact on the brain’s reward pathways.

PCOS, Fertility, and the “Ozempic Babies” Phenomenon

For many women with Polycystic Ovary Syndrome (PCOS), the substantial weight loss from these drugs can restore metabolic balance and regulate menstrual cycles. This has led to enhanced fertility and the recent media phenomenon of “Ozempic babies.”

Other Investigational Uses

Researchers are also observing positive effects in:
Neuroprotection: Patients with dementia and Parkinson’s disease have shown a stall in disease progression, suggesting a neuroprotective effect within the brain.
Latent Autoimmune Diabetes in Adults (LADA): The off-label use of GLP-1 agonists is being studied to help preserve remaining beta-cell function in this form of autoimmune diabetes (Buzzetti et al., 2020).
Respiratory Health: In patients with asthma and COPD, these drugs have been associated with fewer exacerbations, likely due to their anti-inflammatory properties.

The Role of Integrative Chiropractic Care

This is where my perspective as a DC, APRN, and Functional Medicine Practitioner becomes so important. While these medications are incredibly powerful, they are tools, not cures. True, lasting health is achieved when we combine these advanced pharmacotherapies with a foundation of lifestyle and structural wellness.
Optimizing Nervous System Function: The nervous system is the body’s master controller. The gut-brain axis is a two-way communication highway critical for satiety signaling. Chiropractic adjustments can help reduce nerve interference, potentially enhancing the body’s response to these signals and improving the efficiency of the gut-brain connection.
Supporting Musculoskeletal Health During Weight Loss: Rapid and significant weight loss can place new stresses on the body as a patient’s center of gravity shifts. This can lead to new patterns of musculoskeletal pain. Integrative chiropractic care is crucial for managing these biomechanical changes through targeted adjustments, soft-tissue work, and the prescription of corrective exercises.
Addressing the Root Causes: Functional medicine teaches us to ask “Why?” We use a holistic approach to craft personalized nutrition plans, develop sustainable exercise regimens that preserve muscle mass, and implement stress-management techniques to reduce cortisol levels.
Chiropractic care is not an alternative to these medications; it is a vital complement. By ensuring the body’s structure and nervous system function optimally, we create an environment in which these powerful drugs can work most effectively.

Safety, Side Effects, and Practical Recommendations

While transformative, these medications require careful management.

Common GI Side Effects

Nausea: This is the most common side effect, often linked to early satiety.
Constipation or Diarrhea: The effect on motility varies by individual.
Management Strategy: The key is to “start low and go slow.” I start patients on the lowest possible dose for at least a month before considering an increase.

Important Safety Issues

Gallbladder Events: Rapid weight loss can increase the risk of gallstones.
Acute Kidney Injury: Can occur from severe nausea and vomiting leading to dehydration. Staying well-hydrated is critical.
Pancreatitis: Though rare, patients with severe, persistent abdominal pain should seek immediate medical attention.
Surgical Considerations: Anesthesiology guidelines recommend stopping weekly GLP-1 agonists at least one to two weeks before a planned surgery to reduce the risk of aspirating stomach contents.
Muscle and Bone Mass: Significant weight loss involves some loss of lean muscle and bone. I work with patients to incorporate resistance training and ensure adequate protein intake.

Black Box Warning: Thyroid C-Cell Tumors

These medications carry a black box warning regarding the risk of thyroid C-cell tumors observed in rodent studies. While this link has not been established in humans, the drugs are contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Final Thoughts: A New Hope for Patients

The advent of modern GLP-1 receptor agonists has fundamentally changed the landscape of diabetes and metabolic care. For patients like Naomi, starting a GLP-1 agonist is not just about adding another medication; it’s about shifting her disease trajectory. It offers the potential to achieve her A1c goal, lose significant weight, reduce her reliance on insulin, and lower her risk of a future heart attack or stroke.
As healthcare providers, it is our responsibility to embrace a comprehensive, integrative approach. By combining the power of these advanced medications with the foundational principles of lifestyle medicine and chiropractic care, we can offer our patients a new level of hope and empower them to achieve a healthier, more vibrant future.

References


SEO Tags: GLP-1 agonists, Semaglutide, Tirzepatide, Ozempic, Mounjaro, Wegovy, Zepbound, Type 2 Diabetes, Weight Loss, Cardiovascular Risk Reduction, Integrative Chiropractic Care, Functional Medicine, Dr. Alexander Jimenez, El Paso Chiropractor, A1c, Postprandial Glucose, Incretin Effect, Metabolic Health, Heart Health, Kidney Disease, CVOT, Ominous Octet, Gastric Emptying, Satiety, MASH, neuroprotection, PCOS, fertility, LADA, patient-centered care, cardio-renal-metabolic health, chiropractic adjustment, musculoskeletal health

Hormone Optimization Techniques For Thyriod Health

Achieve optimal thyroid health through hormone optimization and support your body’s natural balance and energy.

Abstract

In this educational post, I will explore the nuanced and highly individualized world of hormone optimization, moving beyond rigid, population-based “normal” ranges to focus on patient-centered, evidence-based outcomes. We will delve into the physiological importance of key hormones like testosterone, thyroid hormones (T4 and T3), and progesterone, and discuss the complex considerations surrounding estrogen therapy, particularly for patients with a history of cancer. My goal is to illuminate the rationale behind a functional and integrative approach, emphasizing that true health is about how a patient feels and functions, supported by data, not just about achieving a specific number on a lab report. We will discuss why a low testosterone level, even if the patient feels “normal,” poses significant long-term health risks, including increased all-cause mortality, type 2 diabetes, and Alzheimer’s disease. Furthermore, I’ll explain how integrative chiropractic care, by addressing the body’s structural and neurological integrity, provides a foundational pillar of support for these hormonal therapies, enhancing overall physiological function and patient well-being. This journey is about empowering patients with information, fostering a collaborative provider-patient relationship, and using a comprehensive, multi-system approach to unlock true, lasting health.

The Fallacy of “Normal”: Redefining Hormone Lab Ranges

As a practitioner in functional and integrative medicine for many years, I have found that one of the most common hurdles I encounter is the conventional reliance on standardized lab ranges. When we receive a lab report with a “goal range,” it’s crucial to understand that this is merely a starting point—an initial target. It is not a one-size-fits-all destination for every individual. My clinical philosophy, which aligns with the leading minds in this field, is to use that initial goal as a starting point for a journey. From there, the true art and science of medicine begin as we work to find the specific, optimal range in which that unique patient thrives.
I’ve had countless conversations about this. For example, a man might have a total testosterone level of 300 ng/dL. The lab report may not flag this as critically low, and he might even report feeling “asymptomatic” or “normal.” This is where a deeper, evidence-based understanding is vital.

  • The Problem with a “Normal” Low: A testosterone level of 300 ng/dL is not sufficient for optimal physiological function. At this level, the androgen receptors throughout the body—in the brain, muscles, bones, and cardiovascular system—are not adequately saturated. This undersaturation is a major risk factor.
  • Long-Term Health Risks: Leading researchers like Dr. Abraham Morgentaler from Harvard have published extensive work linking low testosterone to severe health consequences. Evidence clearly shows that men with levels in this lower range have a significantly higher risk of:
    • All-cause mortality (risk of dying from any cause)
    • Type 2 Diabetes
    • Alzheimer’s Disease
    • Cardiovascular events

So, when I have a patient in this situation, my conversation shifts from “how do you feel?” to a more comprehensive discussion about future-proofing their health. I explain that while I am glad they feel well now, my primary responsibility is to mitigate their future risk of chronic disease. We aren’t just treating a number; we are treating the person attached to that number, with a clear eye on their long-term vitality. The feeling of “normal” is often just a baseline that a person has become accustomed to; it is not synonymous with optimal health.

The Interplay of Hormones: A Symphony of Systems

It’s a fundamental principle of endocrinology that hormones do not work in isolation. They function as a complex, interconnected orchestra. If one instrument is out of tune, the entire symphony is affected. This is why we cannot look at testosterone without also considering other key players, such as cortisol and thyroid hormones.
Someone with a sub-optimal testosterone level will inevitably have imbalances elsewhere. Perhaps their sense of “normal” is their body’s maladaptive state. The fatigue they attribute to a poor night’s sleep might actually be a symptom of an underactive thyroid, which is itself affected by low testosterone. This is where a thorough, functional workup becomes indispensable. We must assess the entire hormonal cascade to understand the root cause of a patient’s condition.

Cracking The Low Thyroid Code- Video

The Role of Integrative Chiropractic Care

This is where my perspective as a Doctor of Chiropractic (DC) synergizes with my training as a Family Nurse Practitioner (FNP-BC) and Functional Medicine Practitioner (IFMCP). The nervous system is the master conductor of the endocrine orchestra. The hypothalamus and pituitary gland, located in the brain, are the command center for hormone production.

  • Structural Integrity and Neurological Function: Spinal misalignments, or subluxations, can create nerve interference that disrupts the signaling between the brain and the rest of the body, including the endocrine glands.
  • Stress and the HPA Axis: Chiropractic adjustments have been shown to modulate the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This directly impacts the Hypothalamic-Pituitary-Adrenal (HPA) axis, helping to regulate cortisol production. Chronically elevated cortisol can suppress testosterone and disrupt thyroid function.

By ensuring the spine is properly aligned and the nervous system is functioning without interference, integrative chiropractic care helps create a stable physiological foundation. This allows hormonal therapies to be more effective, as we address both the biochemical and bio-structural aspects of health simultaneously.

Navigating Complex Cases: Hormone Therapy After Diagnosis

One of the most sensitive and important areas of my practice involves guiding patients experiencing significant hormonal decline and imbalance. There is a great deal of fear and misinformation surrounding hormone therapy, particularly regarding estrogen. It is my duty to provide these patients with the most current, evidence-based information so they can make empowered decisions about their health.

Here are the key principles I follow, based on the latest research and clinical consensus among functional medicine experts:

  • Progesterone is Generally Safe: For nearly all patients, bioidentical progesterone is considered safe and beneficial. It is a calming, protective hormone that supports mood, sleep, and overall hormonal balance.
  • Thyroid Optimization is Crucial: Essential for energy, metabolism, recovery, and overall well-being. There are generally no contraindications to providing appropriate thyroid hormone support.

Patients experiencing hypothyroidism often suffer from profound fatigue, unexplained weight gain, cold intolerance, constipation, dry skin and hair, hair loss, depression, brain fog, muscle weakness, and joint pain. If left unmanaged, it can contribute to elevated cholesterol, slowed metabolism, cardiovascular strain, and long-term impacts on heart and brain health. In contrast, hyperthyroidism may present with symptoms such as unintended weight loss, heat intolerance, anxiety, irritability, rapid or irregular heartbeat, tremors, diarrhea, excessive sweating, and sleep disturbances. Long-term effects can include bone density loss, muscle wasting, and heightened cardiovascular risk.

  • Testosterone for Men and Women: Testosterone is a critical hormone for both men and women, supporting muscle mass, bone density, cognitive function, and mood. It can be safely administered with proper monitoring.
  • Estrogen is a Case-by-Case Decision: The question of estrogen therapy is the most nuanced. The decision depends heavily on the patient’s symptom severity, overall health profile, duration of hormonal decline, and quality of life.

Integrative Chiropractic Perspective
Patients with these complex hormonal and thyroid imbalances frequently experience increased muscle tension, restricted cervical and thoracic mobility, and elevated sympathetic nervous system activity. Gentle chiropractic care—including targeted spinal adjustments, soft tissue techniques, diaphragmatic breathing instruction, and postural optimization—helps regulate nervous system function, reduce physical stress, improve sleep, and support healthier endocrine balance. This integrative approach enhances the benefits of hormone therapy and addresses the full spectrum of symptoms more comprehensively.

An Individualized Approach to Estrogen

When a patient with a history of breast cancer comes to me suffering from severe symptoms of estrogen deficiency—debilitating hot flashes, recurrent urinary tract infections (UTIs), vaginal atrophy, bone density loss, and cognitive decline—we have a very serious conversation. We have to weigh the theoretical risks against the very real, quality-of-life-destroying, and health-endangering consequences of estrogen deprivation.
Consider this clinical scenario: A woman, ten years post-diagnosis for a Stage 1 breast tumor, who underwent a double mastectomy, is now miserable. Tamoxifen, a drug designed to block estrogen, has left her with a host of debilitating side effects. Her oncologist offers no alternatives. In this case, she came to me seeking to reclaim her life. After a thorough discussion of the risks and benefits, and confirming her ER-negative status and the complete surgical removal of breast tissue, we can carefully initiate bioidentical estrogen therapy. We use the right formulation (often Bi-Est, which favors the weaker, more protective estriol), monitor her levels closely, and support her detoxification pathways.
What is the alternative? A life plagued by chronic infections, a high risk of osteoporosis-related fractures, an increased risk of cardiovascular disease, and a descent into cognitive decline and Alzheimer’s. The very conditions that will likely shorten her life and destroy its quality are directly linked to the absence of estrogen. Leading research, such as the comprehensive review by Sarrel et al. (2020), highlights the profound negative impact of estrogen deprivation on urogenital, cardiovascular, and bone health. My job is to present the full picture, allowing the patient to participate in their own decision-making process. This right is too often taken away in conventional oncology settings.

The Importance of Thyroid Hormone T3, Especially During Pregnancy

Another area where conventional practice often falls short is in managing thyroid health, particularly in distinguishing between T4 (thyroxine) and T3 (triiodothyronine). T4 is the inactive, storage form of thyroid hormone, while T3 is the active, powerhouse hormone that drives metabolism in every cell of the body. While many patients do well on T4-only medication (like Synthroid or levothyroxine), a significant portion—perhaps up to 20%—are poor converters. Their bodies cannot efficiently turn T4 into the usable T3. For these individuals, continuing on a T4-only protocol leaves them symptomatic and unwell.
This becomes critically important during pregnancy.

  • Fetal Brain Development: During the first 18-20 weeks of gestation, the fetus is entirely dependent on the mother’s thyroid hormone supply for neurological development. Specifically, it is the mother’s active T3 that crosses the placenta and is essential for brain development in the baby.
  • Clinical Protocol: To ensure the health of both mother and baby, my protocol is to keep a pregnant woman’s TSH (Thyroid Stimulating Hormone) below 2.5, and often closer to 1.5, during the first trimester. I ensure she has adequate T3 available. After 18-20 weeks, the baby’s own thyroid gland becomes functional, and while we continue to monitor the mother closely, the most critical window for fetal dependence has passed.

Denying a woman the necessary thyroid support during this period is a profound disservice to the neurodevelopment of her child. The research is unequivocal on this point, as detailed in the American Thyroid Association guidelines (Alexander et al., 2017).

The Power of Patient Empowerment and Building Trust

Ultimately, my role is to serve as an educator and a partner. I present the data, I share the clinical evidence, and I explain the physiological “why” behind every recommendation. Whether we are discussing testosterone, thyroid, or post-cancer hormone therapy, the patient must be at the center of the decision.
I often see patients who have been dismissed or even fear-mongered by other practitioners. They come to me frustrated and hopeless. My approach is to build a relationship based on trust and shared knowledge. I might say, “What you have been doing for the last five years hasn’t worked. Let’s try something different for 12 weeks. We will monitor you closely. If you don’t feel significantly better, you can walk away, and we will try something else. But let’s give your body the tools it needs to heal.”
This collaborative approach is transformative. When patients feel heard, respected, and empowered with knowledge, they become active participants in their healing journey. Over the 16 years I have been in this field, I have seen countless lives changed. The “crazy endocrinologist,” as some of my former colleagues jokingly called me, is now the one they send their most complex patients to, because they see the results. They see patients not just surviving, but truly thriving. And that is the ultimate goal of everything we do.


References

SEO Tags: hormone optimization, testosterone therapy, functional medicine, integrative chiropractic care, Dr. Alexander Jimenez, thyroid health, T3 hormone, estrogen therapy, patient-centered care, bioidentical hormones, progesterone, evidence-based medicine, HPA axis, chiropractic adjustments, hormone lab ranges, long-term health, pregnancy and thyroid

Proactive Healthcare: Putting Patients at the Center

Proactive Healthcare: Putting Patients at the Center

Proactive Healthcare: Putting Patients at the Center

Abstract

This educational post explores the critical need for a paradigm shift in modern medicine, moving from a reactive, symptom-based model to a proactive, patient-centered approach. I will explore the historical context of our current healthcare system, examining the influence of industry and standardized protocols that have led to a “pill for every ill” mentality. We will critically analyze the widespread use of medications like statins and their potential long-term consequences, particularly concerning cognitive health, supported by recent evidence. This discussion will highlight the physiological importance of cholesterol and the risks associated with its suppression. Furthermore, we will address the need for personalized, integrative medicine that accounts for an individual’s unique genetic makeup and lifestyle. I will present a case for prioritizing nutrition, hormone optimization, and root-cause analysis in clinical practice. The goal is to empower fellow practitioners to transcend the limitations of conventional sick care and embrace a proactive wellness model that restores vitality to our patients and reinvigorates our professional calling.

The Historical Shift Towards a Protocol-Driven Model

To understand where we are headed in healthcare, we must first look back at our journey. In the 1800s, medicine began to organize around structured protocols. By the early 1900s, the convergence of science and industry had fundamentally reshaped the landscape. Figures like John D. Rockefeller recognized the immense financial potential within the medical field. Now, let me be clear: I firmly believe that practitioners who do excellent work should be well-compensated. You are saving and improving lives, and your partnership in healing deserves reward.

However, we must also acknowledge the historical precedents where profit has taken precedence over well-being. Industries built around sugar, processed foods, and tobacco generated billions in revenue while contributing to widespread illness and death. When we see this pattern, we must question the systems that allow it.

A major shift occurred in the 1980s with the rise of Big Pharma. This era marked a fundamental shift in medical thinking, moving away from individualized care and toward standardized, protocol-driven treatments. A pivotal moment was in 1987, with the introduction of the first statin medication. This event solidified a new clinical mindset: run a blood test, identify a number that falls outside a “normal” range, and prescribe a pill to correct it. This reductionist approach has shaped the healthcare environment we navigate today.

The Statin Epidemic: Questioning the War on Cholesterol

Let’s examine the most prescribed medications in the United States to understand the scale of this issue. While drugs like metformin and ibuprofen are widely used, statins lead the pack. It’s estimated that by 2025, over 200 million patients will be on a statin. For decades, the prevailing dogma has been to suppress cholesterol levels at all costs. As a clinician, I’ve seen the real-world impact of this practice, and the evidence now compels us to question it.

What do we know about cholesterol? It is not an enemy to be eradicated. Physiologically, it is a foundational component of cellular health. Your brain, by volume, is predominantly built from cholesterol. It is essential for the formation of cell membranes, the synthesis of hormones (like estrogen, testosterone, and cortisol), and the production of vitamin D. When we aggressively lower cholesterol, especially in our aging and hospitalized patients, we are systemically depleting a critical building block.

  • Brain Health and Cholesterol: We are now facing an epidemic of Alzheimer’s disease and other forms of dementia, conditions once considered rare. A growing body of research suggests a correlation between low cholesterol levels and an increased risk of cognitive decline (Sparks et al., 2006). By shrinking the brain’s essential raw material, are we inadvertently contributing to this crisis?
  • Immune Function and Cholesterol: A fascinating study published in February 2025 revealed that cholesterol plays a vital role in fueling dendritic cells, which are key communicators in our immune system. These cells are activated by tumors and help orchestrate a robust immune response against cancer, particularly lung cancer (Ringel et al., 2023). Yet, the standard practice remains to “crush” cholesterol with statins. We must ask if this approach is undermining our body’s innate ability to defend itself.

The “here’s your number, here’s your pill” model is failing us. It treats a lab value as a number on a piece of paper, not the complex human being behind it.

The Systemic Challenge: Big Pharma, Insurance, and Government

The complexities of our healthcare system were amplified in 2010 with the endorsement of the Affordable Care Act. This brought Big Pharma, big insurance, and big government into the same room, all with a vested interest in the industry’s financial mechanics. The global pharmaceutical industry’s net profit in 2024 was an estimated 1.7 trillion dollars. This is pure profit, not top-line revenue. This immense financial success has been achieved within a system that spends trillions annually on “healthcare” while our population grows sicker.

This is the clinical reality I see in my practice and one you likely witness every day. Patients are not getting well. They are being managed, their symptoms bandaged, but the underlying drivers of disease remain unaddressed. This approach is not healing; it’s a cycle of symptom suppression that often leads to more prescriptions to manage the side effects of the first.

The Call for Personalized, Proactive Healthcare

A growing number of patients and practitioners are questioning this broken model. They are demanding something different, something more. The truth is, choice isn’t optional; it’s everything. Medicine has somehow forgotten this fundamental principle. A one-size-fits-all approach is illogical. We are all genetically and biochemically unique. How can we possibly expect the same dose of the same medication, following the same rigid protocol, to work for everyone? It defies common sense.

Today, we stand at a crossroads. We have a choice:

  • Continue as reactive sick-care professionals, waiting for disease to manifest before intervening.
  • Become proactive healthcare providers, empowering our patients to build and maintain wellness.

This requires a shift in mindset. We should aim for our patients to see us to stay well, not just because they are sick. It also requires humility. As a profession, what if admitting we were wrong about certain long-held beliefs is the most important thing we can do to get it right? It takes character to step back from dogma, look at the new evidence, and say, “There is a better way.”

Restoring Curiosity, Humanity, and Critical Thinking

To move forward, we must reintroduce three essential elements into our practice:

  1. Curiosity and Science: We must be lifelong learners, constantly evaluating new research. The principles of functional and integrative medicine are not based on conjecture but are backed by multiple studies. We must be willing to dig deeper and ask why a patient is experiencing symptoms. A person is not Prozac deficient; they are depressed for an underlying reason. Our job is to uncover that root cause.
  2. Humanity: We must remember that we are treating patients, not paper. How often do we find ourselves focused on lab results, reciting numbers, instead of looking our patient in the eye and engaging in a real conversation? The patient’s story, their lived experience, is as crucial as any lab value. We treat fathers, mothers, teachers, and grandparents—the very fabric of our society. Their well-being has a ripple effect on us all.
  3. Critical Thinking: We must challenge the status quo and not accept information without scrutiny. The COVID-19 pandemic, for many of us, was a stark reminder of how easily critical thinking can be suspended in favor of a singular, top-down narrative. When a Stanford virologist stated early on that a safe and effective vaccine would take a minimum of three to four years to develop based on all established scientific standards, it highlighted the unprecedented speed and subsequent controversy of what transpired. I encourage you to question everything, even the information presented here. Take the studies we provide, research them, and come to your own informed conclusions.

The Promise of Integrative and Nutritional Medicine

The good news is that the tide is turning. Major institutions are beginning to acknowledge the vital role of nutrition. A recent article from Johns Hopkins Medicine championed the idea that future doctors will advise on nutrition, fostering a more holistic and comprehensive approach to health (Johns Hopkins Medicine, 2024). This is something we in the functional medicine community have advocated for decades. As I’ve often said, your cells don’t know if they are Republican or Democrat; they only know if they are nourished or starved. Addressing nutrition is not an “alternative” therapy; it is a foundational pillar of health that significantly improves patient outcomes.

Similarly, the evidence supporting the protective roles of hormones is finally gaining traction. For years, we’ve taught that estrogen, when properly balanced and administered, does not cause cancer but, in fact, helps protect the heart, brain, and bones by preventing osteoporosis. The FDA’s willingness to reconsider its stance is a monumental step forward (U.S. Food & Drug Administration, 2023).

Overcoming Cognitive Inertia

One of the biggest obstacles to progress is cognitive inertia—the tendency to stick with default mental models and resist new information that challenges our existing beliefs. It’s confirmation bias in action. Statistically, about 20% of practitioners who attend advanced training and learn new, evidence-based protocols will never implement them. They will return to their comfort zone.

Albert Einstein famously said, “We cannot solve our problems with the same thinking we used when we created them.” We must consciously break free from this inertia. We must move from treating the masses to treating the individual. We must embrace personalized medicine while never losing sight of our shared humanity.

Your Role in the Future of Medicine

Today, March 27, 2026, marks a new beginning. Just as 1987 ushered in the era of the statin, today can be the day you commit to transforming your practice. History doesn’t remember the practitioners who simply followed the system; it remembers those who transformed it. That responsibility now belongs to you.

You have the choice to stay in your comfort zone or to make a change. This is about more than just a new treatment modality; it is about regaining the calling that brought you to medicine in the first place. It’s about seeing your patients return to you not with the same complaints, but with stories of transformation: “You saved my life. You saved my marriage.”

Let’s commit to a new path:

  • Let’s treat patients, not cases.
  • Let’s provide proactive healthcare, not reactive sick care.
  • Let’s be integrative, not just allopathic.
  • Let’s become wellness care providers.

This is our finest hour. Medicine is at a pivotal point, and we are the ones who will drive the change. By restoring freedom to our practice and our patients—freedom from outdated dogma, from censorship, and from a system that ignores our humanity—we can help our communities truly thrive.

References